Vanda Pharmaceuticals Inc
VNDA
Get informed when a big investor buys or sells
+ FollowMarket Cap$306.69M
Close$
$-3.56
166.8% downside
Current Fair Value
166.8% downsideOvervalued by 166.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $306.69 Million |
|---|---|
| Enterprise Value | $259.71 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.74 |
| Beta | 0.6 |
| Outstanding Shares | 59,459,982 |
Return
| Return on Equity | -85.32% |
|---|---|
| Return on Assets | -55.26% |
| Return on Invested Capital | -52.85% |
Valuation & Multiples
| P/E Ratio | -1.26 |
|---|---|
| PEG | -1.95 |
| Price to Sales | 1.78 |
| Price to Book Ratio | 1.33 |
| Enterprise Value to Revenue | 1.19 |
| Enterprise Value to EBIT | -1.65 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.03 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 30, 2026
EPS Estimate
$-0.58
Average shareholder expectationRevenue Estimate
$61.92 M
Average shareholder expectationNext Earnings Call
Expected Date
August 5, 2026
EPS Estimate
$-0.58
Average shareholder expectationRevenue Estimate
$61.92 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 28.18% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 1.05%▼ 77.15% |
|---|---|
| Total Invested | $3.75M▼ 98.83% |
| Investors Holding | 32▼ 142.00% |
ESG Score
No data
About Vanda Pharmaceuticals Inc
CEO: Mihael Polymeropoulos Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients.